Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rena M Conti

Showing results (11-20 of 133) with videos related to

Pageof 14
Sort By:
JAMA Internal Medicine|March 28, 2017
Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014Kao-Ping Chua, Rena M Conti
JAMA Health Forum|January 17, 2025
Marketing and Safety Concerns for Compounded GLP-1 Receptor AgonistsT Joseph Mattingly, Rena M Conti
F1000Research|November 18, 2020
Public research funding and pharmaceutical prices: do Americans pay twice for drugs?Rena M Conti, Frank S David
JAMA Internal Medicine|August 18, 2020
Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19Kao-Ping Chua, Rena M Conti
Journal of General Internal Medicine|July 12, 2022
Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015-2019Kao-Ping Chua, Rena M Conti
Health Affairs (Project Hope)|October 8, 2014
The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communitiesRena M Conti, Peter B Bach
The New England Journal of Medicine|March 3, 2016
Pharmaceutical Policy Reform--Balancing Affordability with Incentives for InnovationRena M Conti, Meredith B Rosenthal
Health Affairs (Project Hope)|October 5, 2020
Trends In Orphan Drug Spending And Out-Of-Pocket Spending Among US Children, 2013-18Kao-Ping Chua, Rena M Conti
American Journal of Preventive Medicine|February 22, 2021
Out-of-Pocket Spending for Influenza Hospitalizations in Medicare AdvantageKao-Ping Chua, Rena M Conti
JAMA|April 24, 2013
Cost consequences of the 340B drug discount programRena M Conti, Peter B Bach
Pageof 14

Showing results (11-20 of 133) with videos related to

Sort By:
Pageof 14
JAMA Internal Medicine|March 28, 2017
Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014Kao-Ping Chua, Rena M Conti
JAMA Health Forum|January 17, 2025
Marketing and Safety Concerns for Compounded GLP-1 Receptor AgonistsT Joseph Mattingly, Rena M Conti
F1000Research|November 18, 2020
Public research funding and pharmaceutical prices: do Americans pay twice for drugs?Rena M Conti, Frank S David
JAMA Internal Medicine|August 18, 2020
Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19Kao-Ping Chua, Rena M Conti
Journal of General Internal Medicine|July 12, 2022
Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015-2019Kao-Ping Chua, Rena M Conti
Health Affairs (Project Hope)|October 8, 2014
The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communitiesRena M Conti, Peter B Bach
The New England Journal of Medicine|March 3, 2016
Pharmaceutical Policy Reform--Balancing Affordability with Incentives for InnovationRena M Conti, Meredith B Rosenthal
Health Affairs (Project Hope)|October 5, 2020
Trends In Orphan Drug Spending And Out-Of-Pocket Spending Among US Children, 2013-18Kao-Ping Chua, Rena M Conti
American Journal of Preventive Medicine|February 22, 2021
Out-of-Pocket Spending for Influenza Hospitalizations in Medicare AdvantageKao-Ping Chua, Rena M Conti
JAMA|April 24, 2013
Cost consequences of the 340B drug discount programRena M Conti, Peter B Bach
Pageof 14